Company news
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) news
Shuttle Pharmaceuticals Holdings, Inc. news releases on 6ix. Latest, Sep 24, 2026: Shuttle Pharmaceuticals : Quarterly Report for Quarter Ending June 30, 2026…
Press releases & updates
Shuttle Pharmaceuticals : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
September 24, 2026
Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter
August 28, 2026
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time
June 8, 2026
Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs
May 13, 2026
E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner
May 7, 2026
Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner
April 30, 2026
RETRANSMISSION, Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
March 30, 2026
RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
March 26, 2026
Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
March 25, 2026
E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals’ $3.5 Million Public Offering
March 12, 2026
Shuttle Pharmaceuticals Announces $3.5 Million Public Offering
March 5, 2026
Shuttle Pharmaceuticals - Utah Approves AI Prescriptions Drugs, How AI Is Saving Time, Cutting Costs and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever
January 14, 2026
Shuttle Pharmaceuticals Acquires AI Health Platform
November 21, 2025
Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00
November 3, 2025
Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)
October 21, 2025
Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform
October 21, 2025
Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)
October 20, 2025
Shuttle Executes LOI with Molecule.ai
October 10, 2025
Shuttle to Enter $3.24 Billion AI Pharmaceutical Market
October 9, 2025
Shuttle Pharma Provides Second Quarter 2025 Corporate Update
August 14, 2025
Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
June 24, 2025
Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
June 20, 2025
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
June 12, 2025
Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
June 12, 2025
Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors
June 4, 2025
Shuttle Pharma Provides Corporate Update
May 15, 2025
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
May 8, 2025
Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
April 21, 2025
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
April 10, 2025
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
March 13, 2025
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
March 12, 2025
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
March 12, 2025
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
February 26, 2025
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
January 20, 2025
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 6, 2025
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
December 18, 2024
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
November 25, 2024
Shuttle Pharma Pays Off Senior Secured Convertible Note
October 28, 2024
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
October 28, 2024
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
October 28, 2024
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
October 27, 2024
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
September 15, 2024
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
September 4, 2024
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
September 3, 2024
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 27, 2024
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
August 25, 2024
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
August 13, 2024
Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
June 17, 2024
Shuttle Pharma Provides First Quarter 2024 Corporate Update
May 13, 2024
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
March 20, 2024